Phase III IMpower150 study showed Roche ’s TECENTRIQ (atezolizumab) and Avastin (bevacizumab) plus carboplatin and paclitaxel helped people with advanced lung cancer live longer compared to Avastin plus carboplatin and paclitaxel

Roche today announced that the Phase III IMpower150 study met its co-primary endpoint of overall survival (OS) at this interim analysis and showed that initial (first-line) treatment with the combination of TECENTRIQ ® (atezolizumab) and Avastin® (bevacizumab) plus carboplatin and paclitaxel (chemotherapy) helped people with advanced non-squamous non-small cell lung cancer (NSCLC) live significantly longer compared with Avastin plus carboplatin and paclitaxel.
Source: Roche Media News - Category: Pharmaceuticals Source Type: news

Related Links:

Authors: Lantuejoul S, Damotte D, Hofman V, Adam J Abstract Lung cancer is the leading cause of cancer death worldwide with low response rates to conventional chemotherapy. New promising therapies have emerged based on programmed cell death protein 1 (PD-1) immunity checkpoint inhibitors (ICI), including anti-PD-1, such as nivolumab and pembrolizumab, or programmed death ligand 1 (PD-L1) inhibitors, such as atezolizumab, durvalumab, and avelumab. The prescription of pembrolizumab has been approved by FDA and EMA for advanced stages non-small cell lung carcinoma (NSCLC), restricted for first-line setting to patients...
Source: Journal of Thoracic Disease - Category: Respiratory Medicine Tags: J Thorac Dis Source Type: research
A biotechnology company specializing in innovative cancer therapeutics has opened a clinical trial examining an immunotherapy drug targeting a protein found in 90 percent of malignant mesothelioma tumors. It is the first clinical trial to specifically study a patient population characterized by this protein expression. The target is known as VISTA, a surface protein which inhibits the immune system from working properly and allows the mesothelioma to grow. The drug is CA-170, an orally available molecule and the only anti-VISTA drug being studied today in a cancer clinical trial. And the potential could be huge. “The...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
In recent years, multiple actionable oncogenic drivers and corresponding targeted agents have been identified in non-small-cell lung cancer (NSCLC) patients. In patients with activating epidermal growth factor receptor (EGFR) mutations improved outcomes with respect to response rate (ORR), progression-free survival (PFS), and quality of life were demonstrated with first- or second-generation EGFR tyrosine kinase inhibitors (TKIs) in comparison to standard first line platinum-based chemotherapy [1 –6].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
Opinion statementThe treatment of advanced non-small cell lung cancer (NSCLC) has evolved to include targeted therapy, immunotherapy as well as chemotherapy for selected patients in the first-line setting. Angiogenesis inhibitors have been used in combination with chemotherapy in the first-line and maintenance settings providing improved progression-free survival (PFS) and objective response rate (ORR), as well as overall survival (OS) in selected studies. Biologic rationale exists for combining anti-angiogenic agents with immunotherapy and targeted kinase inhibitors (TKIs). A recent study has demonstrated improved surviva...
Source: Current Treatment Options in Oncology - Category: Cancer & Oncology Source Type: research
Our study shows that retinoblastoma (RB1) mutation is associated with decreased overall survival in patients with locally advanced and advanced non small cell lung cancer. We also show thatRB1 mutation correlates with lack of response to immunotherapy. AbstractThe retinoblastoma gene (RB1) encodes the retinoblastoma (RB) pocket protein that plays an important role in cell cycle progression. Here we determine the frequency and prognostic significance ofRB1 mutation in non small cell lung cancer (NSCLC), restricting inclusion to Stage III and IV patients with linked genomic and clinical data. The primary outcome was median o...
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research
Condition:   Carcinoma, Non-Small-Cell Lung Interventions:   Drug: Cisplatin;   Drug: Carboplatin;   Drug: Pemetrexed;   Drug: Nab-paclitaxel;   Drug: Gemcitabine;   Drug: Docetaxel;   Drug: M7824 Sponsors:   EMD Serono Research & Development Institute, Inc.;   Merck KGaA, Darmstadt, Germany Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Abstract OBJECTIVEConcurrent use of anti-PD-1 therapies with stereotactic radiosurgery (SRS) have been shown to be beneficial for survival and local lesional control in melanoma patients with brain metastases. It is not known, however, if immunotherapy (IT) confers the same outcome advantage in lung cancer patients with brain metastases treated with SRS.METHODSThe authors retrospectively reviewed 85 non-small cell lung cancer (NSCLC) patients with brain metastases who were treated with SRS between January 2006 and December 2016. Thirty-nine PD-L1 antibody-positive patients received anti-PD-1 therapy with SRS (IT g...
Source: Journal of Neurosurgery - Category: Neurosurgery Authors: Tags: J Neurosurg Source Type: research
Abstract BACKGROUND: Malignant airway obstruction (MAO) occurs in 30% of patients with advanced stage lung cancer leading to debilitating dyspnea, cough and hemoptysis. Other than recanalization of the airways, these patients lack long-lasting palliative therapy. The goal of this study was to determine the safety and feasibility of local injection of paclitaxel into the airway wall with a novel microinjection catheter. METHODS: In this multicentered prospective trial, 23 patients with non-small cell lung cancer (NSCLC) and MAO from July 2014 through June 2016 were enrolled to undergo rigid bronchoscopy with r...
Source: Chest - Category: Respiratory Medicine Authors: Tags: Chest Source Type: research
CONCLUSION: Our experience suggests an encouraging efficacy of nintedanib/docetaxel in patients with adenocarcinoma NSCLC pretreated with platinum-based doublet chemotherapy and immunotherapy, reinforcing the importance of an optimal therapeutic sequence for managing advanced lung adenocarcinoma. PMID: 30771085 [PubMed - as supplied by publisher]
Source: Clinical Lung Cancer - Category: Cancer & Oncology Authors: Tags: Clin Transl Oncol Source Type: research
In this study, out data showed endostar plus platinum ‐based doublet chemotherapy was well tolerated and significantly improved the progression‐free survival, overall survival, and disease control rate in patients with advanced non‐small cell lung cancer. The once‐daily 7‐day administration regimen of endostar was not inferior to the once‐d aily 14‐day administration regimen of endostar in efficacy and safety. The once‐daily 7‐day administration regimen of endostar needs further studies before its adoption in clinical work. AbstractAimsThis real ‐world study is conducted to evaluate the efficacy and saf...
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research
More News: Avastin | Cancer | Cancer & Oncology | Chemotherapy | Lung Cancer | Non-Small Cell Lung Cancer | Pharmaceuticals | Study